ArticleCancer immunology, immunotherapy : CII2026
Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitor (ICI) rechallenge in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) is a promising therapeutic strategy. We aim to assess its treatment outcomes and build prognostic models for clinical practice.
methodsR/M NPC patients who failed prior anti-PD-1 immunotherapy and received ICI rechallenge were enrolled. Clinical features were recorded, and univariate and multivariate analysis was conducted to evaluate prognostic factors. Prognostic models were developed and validated to predict progression-free survival (PFS) and overall survival (OS), respectively.
resultsA total of 243 patients were enrolled between January 2019 and December 2023. The objective response rate (ORR) and disease control rate (DCR) for the entire cohort were 24.3% and 75.7%, respectively. After a median follow-up of 10.5 months, the median PFS was 6.3 months, the median duration of response (DOR) was 9.8 months, and the median OS was 19.8 months. Multivariate Cox analysis identified that the latest efficacy of anti-PD-1 therapy (HR 0.587, 95%CI 0.357-0.963, p = 0.035), EBV DNA level (HR 1.743, 95%CI 1.252-2.426, p = 0.001), locoregional therapy (HR 0.467, 95%CI 0.268-0.812, p = 0.007), and rechallenge with anti-PD-1 inhibitor (HR 1.548, 95%CI 1.005-2.385, p = 0.047) were independent statistically prognostic factors for PFS. Additionally, age (HR 2.044, 95%CI 1.297-3.222, p = 0.002), bone metastatic (HR 1.642, 95%CI 1.055-2.555, p = 0.028), and EBV DNA level (HR 1.673, 95%CI 1.034-2.706, p = 0.036) were independent significantly associated with OS. Prognostic models were developed based on the risk factors. Stratification of patients by the prognostic scores from these models showed that the low-risk group patients had significantly improved PFS and OS compared to their high-risk counterparts.
conclusionsThis study provided a comprehensive assessment of the efficacy and prognostic factors of ICI rechallenge in RM-NPC patients who failed prior anti-PD-1 immunotherapy, and developed a prognostic model which could identify candidates for ICI rechallenge. Further prospective trials are warranted to confirm and expand these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.